Who are in the management team of Narayana Hrudaya?

As of March 2022, the management team of Narayana Hrudaya includes Chairman Devi Prasad Shetty, Executive Vice Chairman Viren Shetty, Managing Director Emmanuel Rupert, and several independent directors, totaling a diverse leadership structure.

As of March 2022, the management team of Narayana Hrudaya includes the following individuals:<BR><BR>1. Devi Prasad Shetty - Chairman & Wholetime Director<BR>2. Viren Shetty - Executive Vice Chairman<BR>3. Emmanuel Rupert - Managing Director & Group CEO<BR>4. Kiran Mazumdar Shaw - Director<BR>5. Dinesh Krishna Swamy - Independent Director<BR>6. B Muthuraman - Independent Director<BR>7. B N Subramanya - Independent Director<BR>8. Arun Seth - Independent Director<BR>9. Terri Smith Bresenham - Independent Director<BR>10. Nachiket Mor - Independent Director<BR>11. Shankar Arunachalam - Independent Director<BR>12. Naveen Tewari - Independent Director<BR>13. Sridhar S - Company Secretary & Compliance Officer<BR><BR>This team comprises a mix of executive and independent directors, reflecting a diverse leadership structure within the company.

When is the next results date for Narayana Hrudaya?

No Upcoming Board Meetings

Has Narayana Hrudaya declared dividend?

Narayana Hrudayalaya Ltd has declared a 40% dividend, amounting to ₹4 per share, with an ex-date of August 2, 2024. The company has shown strong price appreciation over various periods, with total returns reaching 515.5% over the past five years.

Narayana Hrudayalaya Ltd has declared a 40% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 40%<BR>- Amount per share: 4<BR>- Ex-date: 02 Aug 24<BR><BR>Dividend Yield: 0.23%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 30.76%, with a dividend return of 0%, resulting in a total return of 30.76%.<BR><BR>Over the past year, the price return stood at 40.91%, with a dividend return of 0.32%, leading to a total return of 41.23%.<BR><BR>In the 2-year period, the price return was 94.69%, while the dividend return was 0.65%, culminating in a total return of 95.34%.<BR><BR>For the 3-year period, the price return reached 168.32%, with a dividend return of 1.18%, resulting in a total return of 169.5%.<BR><BR>In the last 4 years, the price return was 254.6%, with a dividend return of 1.55%, leading to a total return of 256.15%.<BR><BR>Over the past 5 years, the price return was 512.7%, with a dividend return of 2.80%, resulting in a total return of 515.5%.<BR><BR>Overall, Narayana Hrudayalaya Ltd has declared a significant dividend, and the total returns over various periods indicate strong price appreciation, particularly over the longer term, despite relatively low dividend returns.

Who are the peers of the Narayana Hrudaya?

Narayana Hrudaya's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Global Health, Aster DM Health, Krishna Institute, Rainbow Child, Dr. Agarwal's Health, and Jupiter Life Line. It has good growth and capital structure, with a 1-year return of 50.16%, lower than Krishna Institute's 85.63%.

Peers: The peers of Narayana Hrudaya are Max Healthcare, Apollo Hospitals, Fortis Health, Global Health, Aster DM Health, Krishna Institu, Rainbow Child, Dr Agarwal's Hea, and Jupiter Life Lin.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Fortis Health, Global Health, Krishna Institu, Rainbow Child, Dr Agarwal's Hea, Jupiter Life Lin, and Narayana Hrudaya, while Average management risk is found at Aster DM Health. Growth is excellent at Max Healthcare and Apollo Hospitals, good at Narayana Hrudaya and Fortis Health, while below average growth is noted at Aster DM Health and Krishna Institu, with the rest having average or good growth. Capital structure is excellent at Max Healthcare, Global Health, and Krishna Institu, good at Narayana Hrudaya, Fortis Health, and Rainbow Child, while below average capital structure is seen at Aster DM Health.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krishna Institu at 85.63%, while the lowest is Dr Agarwal's Hea, which has no available data. Narayana Hrudaya's 1-year return is 50.16%, which is lower than Krishna Institu's but higher than many others. Additionally, Aster DM Health and Dr Agarwal's Hea have negative six-month returns.

Is Narayana Hrudaya overvalued or undervalued?

As of June 30, 2025, Narayana Hrudaya is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 55.72 and an EV to EBITDA of 35.36, despite a strong year-to-date return of 71.05%, suggesting caution for investors.

As of 30 June 2025, the valuation grade for Narayana Hrudaya has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 55.72, an EV to EBITDA of 35.36, and a PEG ratio of 46.64. In comparison, Apollo Hospitals, which is rated attractive, has a PE ratio of 71.96 and an EV to EBITDA of 36.11, while Fortis Health, also expensive, has a PE ratio of 71.25 and an EV to EBITDA of 38.89.<BR><BR>Despite the recent stock performance, which has outpaced the Sensex with a year-to-date return of 71.05% compared to the Sensex's 7.00%, the high valuation ratios indicate that Narayana Hrudaya is trading at a premium relative to its peers. Therefore, investors should approach this stock with caution given its current overvaluation status.

What does Narayana Hrudaya do?

Narayana Hrudayalaya Ltd is a large-cap company providing medical and healthcare services, founded by Dr. Devi Prasad Shetty in 2000. As of March 2025, it reported net sales of ₹14,754 Cr and a net profit of ₹1,972 Cr.

Overview: <BR>Narayana Hrudayalaya Ltd is primarily engaged in rendering medical and healthcare services within the hospital industry and is categorized as a large-cap company.<BR><BR>History: <BR>Narayana Hrudayalaya Ltd was incorporated on 19 July 2000 by Dr. Devi Prasad Shetty. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 14,754 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,972 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 40,324 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 50.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.20% <BR>Debt-Equity: 0.22 <BR>Return on Equity: 21.96% <BR>Price to Book: 11.19 <BR><BR>Contact Details: <BR>Address: No 258/A Bommasandra Indl Area, Anekal Taluq Bengaluru Karnataka : 560099 <BR>Tel: 91-80-71222802 <BR>Email: investorrelations@narayanahealth.or <BR>Website: http://www.narayanahealth.org

Who are the top shareholders of the Narayana Hrudaya?

The top shareholders of Narayana Hrudaya include Shakuntala Shetty with 35.38%, 22 mutual fund schemes holding 5.71%, 217 foreign institutional investors with 9.66%, and Kiran Mazumdar Shaw as the highest public shareholder at 2.3%. Individual investors collectively own 11.47% of the shares.

The top shareholders of Narayana Hrudaya include the promoters, with Shakuntala Shetty being the largest individual shareholder, holding 35.38% of the company. There are also 22 mutual fund schemes collectively holding 5.71% and 217 foreign institutional investors (FIIs) with a combined holding of 9.66%. Additionally, Kiran Mazumdar Shaw is noted as the highest public shareholder, owning 2.3%. Individual investors collectively hold 11.47% of the shares.

How big is Narayana Hrudaya?

As of 24th July, Narayana Hrudayalaya Ltd has a market capitalization of 40,715.00 Cr, with net sales of 5,550.99 Cr and a net profit of 790.16 Cr reported in the latest four quarters. The company has shareholder's funds of 2,883.68 Cr and total assets of 5,619.27 Cr.

As of 24th July, Narayana Hrudayalaya Ltd has a market capitalization of 40,715.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Narayana Hrudayalaya reported net sales of 5,550.99 Cr and a net profit of 790.16 Cr.<BR><BR>For the latest annual period, the company reported shareholder's funds of 2,883.68 Cr and total assets of 5,619.27 Cr.

Are Narayana Hrudaya latest results good or bad?

Narayana Hrudayalaya's latest results show mixed performance, with record quarterly net sales of Rs 1,507.27 crore but declines in operating profit by 5.81% and net profit by 0.28%, alongside rising interest expenses and a higher debt-equity ratio, indicating financial challenges ahead.

Narayana Hrudayalaya's latest financial results indicate a mixed performance. On the positive side, the company achieved its highest quarterly net sales in the last five quarters, totaling Rs 1,507.27 crore, reflecting a 2.16% growth compared to the previous quarter. This suggests a favorable trend in sales.<BR><BR>However, there are significant challenges as well. The company's operating profit has declined by 5.81%, and its net profit has seen a slight decrease of 0.28%. Additionally, the operating profit to interest ratio has dropped to its lowest point in five quarters, which raises concerns about the company's ability to manage interest payments effectively. The interest expense has increased by 11.01%, indicating that the company is likely increasing its borrowings, which is further supported by a rising debt-equity ratio of 0.67 times.<BR><BR>Overall, while there are some positive sales figures, the decline in profitability and increasing financial strain suggest that the results are not entirely favorable. The company faces challenges that could impact its financial health moving forward.

How has been the historical performance of Narayana Hrudaya?

Narayana Hrudaya has shown strong financial growth, with net sales increasing from 2,582.35 crore in March 2021 to 5,482.98 crore in March 2025, and profit before tax improving from a loss of 49.23 crore to a profit of 935.54 crore during the same period. The company's total assets rose significantly, indicating robust expansion and improved profitability.

Answer:<BR>The historical performance of Narayana Hrudaya shows a consistent growth trajectory in net sales, which increased from 2,582.35 crore in March 2021 to 5,482.98 crore in March 2025. The total operating income followed a similar trend, reaching 5,482.98 crore in March 2025, up from 2,582.35 crore in March 2021. Operating profit (PBDIT) also saw significant growth, climbing to 1,368.43 crore in March 2025 from 210.29 crore in March 2021. Profit before tax improved from a loss of 49.23 crore in March 2021 to a profit of 935.54 crore in March 2025, while profit after tax increased to 789.82 crore in March 2025 from a loss of 7.45 crore in March 2021. The company's total assets rose from 2,889.06 crore in March 2020 to 7,257.31 crore in March 2025, indicating strong asset growth. Total liabilities also increased, reaching 7,257.31 crore in March 2025, up from 2,889.06 crore in March 2020. Cash flow from operating activities was robust, amounting to 985 crore in March 2025, although cash flow from investing activities showed a significant outflow of 1,324 crore. The company maintained a positive net cash inflow of 205 crore in March 2025.<BR><BR>Breakdown:<BR>Narayana Hrudaya's financial performance over the years reflects a strong upward trend in key metrics. Net sales surged from 2,582.35 crore in March 2021 to 5,482.98 crore in March 2025, while total operating income mirrored this growth, reaching the same figure. The operating profit (PBDIT) increased significantly, from 210.29 crore in March 2021 to 1,368.43 crore in March 2025, showcasing improved operational efficiency. Profit before tax transitioned from a loss of 49.23 crore in March 2021 to a profit of 935.54 crore in March 2025, and profit after tax followed suit, rising to 789.82 crore from a loss of 7.45 crore. The total assets of the company expanded from 2,889.06 crore in March 2020 to 7,257.31 crore in March 2025, indicating substantial growth in resources. Total liabilities also increased, reflecting the company's expansion strategy. Cash flow from operating activities remained strong at 985 crore in March 2025, although the company experienced a notable outflow in cash flow from investing activities. Overall, Narayana Hrudaya has demonstrated robust growth and improved profitability over the years.

Is Narayana Hrudaya technically bullish or bearish?

As of November 17, 2025, Narayana Hrudaya's trend is bullish, supported by strong MACD and Bollinger Bands indicators, although a bearish KST signal on the weekly chart slightly tempers the overall outlook.

As of 17 November 2025, the technical trend for Narayana Hrudaya has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend in both time frames. Daily moving averages are bullish, reinforcing the upward momentum. However, the KST shows a bearish signal on the weekly, which slightly tempers the overall bullish outlook. The Dow Theory reflects a mildly bullish stance on both weekly and monthly charts. Overall, the strength of the bullish trend is supported by multiple indicators, despite some mixed signals in the KST.

Should I buy, sell or hold Narayana Hrudaya?

Which are the latest news on Narayana Hrudaya?

Why is Narayana Hrudaya falling/rising?

As of 18-Dec, Narayana Hrudayalaya Ltd's stock price is at 1,836.00, reflecting a decline of 1.95%. Despite strong long-term fundamentals, the stock is currently underperforming, with reduced investor interest and a high PEG ratio contributing to its recent price drop.

As of 18-Dec, Narayana Hrudayalaya Ltd's stock price is falling, currently at 1,836.00, which reflects a decrease of 36.5 points or 1.95%. The stock has been underperforming, having lost 3.36% over the last three days and showing a weekly decline of 2.62%, while the broader Sensex index has only decreased by 0.40% during the same period. <BR><BR>Today's performance indicates that the stock has underperformed its sector by 1.33%. Additionally, the stock touched an intraday low of Rs 1,823.9, indicating significant selling pressure. There is also a noted decline in investor participation, with delivery volume falling by 6.37% compared to the five-day average, suggesting reduced interest from investors.<BR><BR>Despite the long-term positive fundamentals, such as a strong Return on Capital Employed (ROCE) of 25.88% and healthy growth in operating profit, the stock's current valuation appears expensive with a PEG ratio of 4.6. This could be contributing to the recent price decline as investors may be reassessing the stock's value in light of its recent performance and market conditions.